Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 17;6(7):e741.
doi: 10.1097/HS9.0000000000000741. eCollection 2022 Jul.

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)

Axel Rüfer  1 , Hubert Angermann  2 , Rudolf Benz  3 , Nicolas Bonadies  4 , Antonello Calderoni  5 , Nathan Cantoni  6 , Anna Efthymiou  7 , Robert Escher  8 , Geneviève Favre  9 , Dorothea Friess  10 , Andreas Gschwend  11 , Andreas Himmelmann  12 , Andreas Holbro  13 , Peter Keller  14 , Eirini Kouroupi  15 , Thomas Lehmann  16 , Nikolaus Pedarnig  2 , Véronique Rigamonti  17 , Kaveh Samii  18 , Adrian Schmidt  19 , Hans-Peter Schäfer  20 , Roland Sperb  21 , Georg Stüssi  22 , Annette Winkler  23 , Reinhard Zenhäusern  24 , Jeroen S Goede  25
Affiliations

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)

Axel Rüfer et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Prognostic scoring systems at diagnosis of MDS. (A) IPSS at diagnosis of MDS, (B) IPSS-R at diagnosis of MDS, and (C) WPSS at diagnosis of MDS. IPSS = International Prognostic Scoring System; IPSS-R = Revised International Prognostic Scoring System; MDS = myelodysplastic syndromes; WPSS = WHO Classification-based Prognostic Scoring System.
Figure 2.
Figure 2.
Median OS. (A) Kaplan-Meier curve for median OS as of start of treatment with lenalidomide according to RBC transfusions during cycle 1 of treatment with lenalidomide in 61 patients with at least 6 documented treatment cycles. There was a significant longer median OS in those 30 patients who received no RBC transfusions during the first cycle of treatment with lenalidomide of 6.7 y (95% CI, 3.9-9.6) compared with 31 patients who did receive RBC transfusions during that time of 3.34 y (95% CI, 2.56-4.12; P = 0.014). (B) Kaplan-Meier curve for median OS as of start of treatment with lenalidomide according to initial diagnosis of MDS. There was a significant longer median OS of 6.7 y (95% CI, 3.0-10.4) in those 55 patients with MDS with isolated del(5q) compared with 2.4 y (95% CI, 1.99-2.9) in 28 patients with other entities of MDS (P = 0.004). CI = confidence intervals; MDS = myelodysplastic syndromes; OS = overall survival; RBC = red blood cells.
See this image and copyright information in PMC

References

    1. Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383:1358–1374. - PubMed
    1. Malcovati L, Hellström-Lindberg E, Bowen D, et al. . Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–2964. - PMC - PubMed
    1. Fenaux P, Haase D, Santini V, et al. . Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆. Ann Oncol. 2021;32:142–156. - PubMed
    1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines). Myelodysplastic Syndromes. Version 2. 2022. Available at: www.nccn.org/professionals. Accessed November 29, 2021.
    1. List A, Dewald G, Bennett J, et al. . Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–1465. - PubMed